Abstract 88P
Background
With lung remains the second common site of colon-rectal cancer metastasis, it is still a challenge for early detection and finding. Therefore, we evaluate the CT-based radiomics of indeterminate lung nodules, predicting lung metastasis and prognosis in locally advanced rectal cancer patients.
Methods
A retrospective review for lung metastatic patients with colon-rectal cancer (CRC) and chest CT images were conducted. Radiomic prediction model of lung metastasis was trained by 114 patients with pathologically verified lung metastasis and 122 patients with benign lung nodules. We investigate the value of radiomics for identifying lung metastasis in 174 locally advanced rectal cancer(LARC) patients with follow-up information. Then, we conducted a Cox model and Kaplan-Meier curve analysis based on radiomics risk scores, and compare them to a clinical-pathological model for prognostic prediction. We use LASSO and linear regression to generated the radiomics model. C-index was used to assess model performance.
Results
For lung metastatic nodule identification in CRC patient, the C-index was 0.794(95%CI 0.784 -0.803) in the training set and 0.752(95%CI 0.728-0.776) in the validation set. In LARC patients, the C-index for lung metastatic identification was 0.771(95%CI 0.763-0.780). For prognostic prediction in LARC patients, ypTNM stage had a great influence on prognosis(Log-rank test P=0.003), and the C-index was 0.695 (95%CI 0.638-0.752). The C-index for nodules was 0.663(95%CI 0.575-0.751) with HR=1.148 (95% 1.050-1.256, P=0.003), and P<0.001 for Log-rank test. The combination of the ypTNM stage and nodule radiomics information has the C-index of 0.757 (95%CI 0.692-0.822), with P<0.001 for Log-rank test, which increase the performance of clinical prognostic prediction(P= 0.044).
Conclusions
Radiomics for nodules can determine lung metastasis in LARC patients. Lung nodules radiomics can provide information for prognostic analysis. The combination of lung nodules radiomics and ypTNM information increases the performance of prognostic prediction in LARC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session